[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"central-nervous-system-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:central-nervous-system-neoplasm":37},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,55,176,215,234,256],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":39,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100640818","studying-the-workflow-of-the-american-college-of-surgeons-geriatric-surgery-program-to-improve-clinical-outcomes-in-older-adults-undergoing-surgery-at-the-james-cancer-hospital-100640818",false,"NCT07606287","Studying the Workflow of the American College of Surgeons Geriatric Surgery Program to Improve Clinical Outcomes in Older Adults Undergoing Surgery at the James Cancer Hospital","Implementation of the American College of Surgeons Geriatric Surgery Verification Program at the James Cancer Hospital","Inclusion Criteria:\n\n1. Patient records for adults aged 65 years or older\n2. Patient records with a surgical encounter or preoperative evaluation within participating James Cancer Hospital surgical oncology services during the rollout period\n3. Patient records with data available in institutional electronic health record or institutional data systems\n4. Clinical staff age 18 years or older who are employed or credentialed at The Ohio State University Wexner Medical Center and work within clinical areas affected by ACS Geriatric Surgery Verification implementation\n\nExclusion Criteria:\n\n1. Patient records for encounters occurring only at outside institutions or non-James hospitals within the enterprise\n2. Patient records missing all primary outcome fields after data quality checks\n3. Clinical staff who are trainees, including medical students, physician assistant students, nursing students, resident physicians, or fellows\n4. Clinical staff whose employment, visa, or institutional status would make participation sensitive under institutional policy, if applicable",true,"ALL","18 Years",{"count":20,"type":21},4000,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study examines how the American College of Surgeons Geriatric Surgery Verification Program, also called the ACS GSV Program, is implemented at the James Cancer Hospital. The program is designed to improve surgical care for adults age 65 and older by helping care teams identify and address age-related needs before, during, and after surgery.\n\nOlder adults with cancer may have concerns related to physical function, memory or thinking, medications, social support, and goals of care. If these needs are not recognized, patients may be at higher risk for complications, longer hospital stays, readmission, or discharge to a facility instead of home.\n\nThe ACS GSV Program includes standards for geriatric surgery leadership, goals-of-care discussions, screening for age-related vulnerabilities, care plans for identified needs, age-friendly perioperative care, and regular review of surgical outcomes. This study will evaluate how well these standards are adopted across surgical oncology services and whether implementation is associated with better outcomes, such as shorter hospital stays, fewer complications, fewer readmissions, and improved discharge outcomes.\n\nThe results may help improve surgical care workflows for older adults undergoing cancer surgery.",[27,28,29,30,31,32,33,34,35,36,37,38],"Breast Carcinoma","Malignant Digestive System Neoplasm","Malignant Female Reproductive System Neoplasm","Malignant Genitourinary System Neoplasm","Malignant Head and Neck Neoplasm","Malignant Nervous System Neoplasm","Malignant Solid Neoplasm","Malignant Thoracic Neoplasm","Skin Neoplasm","Soft Tissue Neoplasm","Central Nervous System Neoplasm","Endocrine Gland Neoplasms",[40,41],"geriatric surgery verification","oncogeriatrics","NOT_YET_RECRUITING","2026-05-27",{"date":45,"type":46},"2026-05-29","ACTUAL",{"date":48,"type":21},"2026-06-15",{"date":50,"type":21},"2027-12-31",{"name":52,"class":53},"Ohio State University Comprehensive Cancer Center","OTHER",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":66,"conditions":67,"keywords":4,"overallStatus":166,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":173,"locationsCount":175},"100612878","social-health-activity-behaviors-and-quality-of-life-among-young-adult-cancer-survivors-100612878","NCT07259304","Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors","Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors: A Longitudinal Study","Inclusion Criteria:\n\n* Diagnosed and\u002For treated with cancer between ages 18-39 at USC hospitals.\n* Cancer types prototypical for adolescents and young adults (AYAs) and cancer stages I-III; select patients with stage IV disease may be eligible, with approval by the principal investigator (PI) and in consultation with the treating clinician.\n* Must be within three months of a de novo cancer diagnosis at recruitment and on\u002Findicated for curative therapy (any modality). Patients may continue on adjuvant therapy throughout duration of the study.\n* Patients must have anticipated survival of \\>1-year at time of diagnosis.\n\nExclusion Criteria:\n\n* Diagnosis of blood malignancies such as leukemias (these cancers have divergent treatment patterns of longer duration than other cancers and are more commonly pediatric cancers). Some early stage lymphomas with favorable prognoses may be eligible, with approval by the PI and in consultation with the treating clinician.\n* Primary language other than English or Spanish.\n* Inability to complete a survey and\u002For wear an accelerometer either per the patient or in consultation with the clinician's judgment.","39 Years",{"count":64,"type":21},250,"OBSERVATIONAL","This study assesses how personal relationships (such as friendships, family relationships, or romantic partners) influence the physical activity (exercise) and well-being of young adult cancer survivors. Researchers also hope to learn how social relationships change after a cancer diagnosis, and how these changes might impact important health behaviors. The information provided may help researchers learn more about better ways to support young cancer patients in the future through interventions that help maintain good social relationships and health levels of physical activity.",[68,69,70,71,72,73,74,75,76,77,37,78,79,80,81,82,83,84,85,86,87,88,33,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165],"Anatomic Stage I Breast Cancer AJCC v8","Anatomic Stage IA Breast Cancer AJCC v8","Anatomic Stage IB Breast Cancer AJCC v8","Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage IIA Breast Cancer AJCC v8","Anatomic Stage IIB Breast Cancer AJCC v8","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IIIA Breast Cancer AJCC v8","Anatomic Stage IIIB Breast Cancer AJCC v8","Anatomic Stage IIIC Breast Cancer AJCC v8","Clinical Stage I Cutaneous Melanoma AJCC v8","Clinical Stage IA Cutaneous Melanoma AJCC v8","Clinical Stage IB Cutaneous Melanoma AJCC v8","Clinical Stage II Cutaneous Melanoma AJCC v8","Clinical Stage IIA Cutaneous Melanoma AJCC v8","Clinical Stage IIB Cutaneous Melanoma AJCC v8","Clinical Stage IIC Cutaneous Melanoma AJCC v8","Clinical Stage III Cutaneous Melanoma AJCC v8","Hodgkin Lymphoma","Malignant Bone Neoplasm","Malignant Brain Neoplasm","Malignant Testicular Neoplasm","Non-Hodgkin Lymphoma","Pathologic Stage I Cutaneous Melanoma AJCC v8","Pathologic Stage IA Cutaneous Melanoma AJCC v8","Pathologic Stage IB Cutaneous Melanoma AJCC v8","Pathologic Stage II Cutaneous Melanoma AJCC v8","Pathologic Stage IIA Cutaneous Melanoma AJCC v8","Pathologic Stage IIB Cutaneous Melanoma AJCC v8","Pathologic Stage IIC Cutaneous Melanoma AJCC v8","Pathologic Stage III Cutaneous Melanoma AJCC v8","Pathologic Stage IIIA Cutaneous Melanoma AJCC v8","Pathologic Stage IIIB Cutaneous Melanoma AJCC v8","Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","Pathologic Stage IIID Cutaneous Melanoma AJCC v8","Prognostic Stage I Breast Cancer AJCC v8","Prognostic Stage IA Breast Cancer AJCC v8","Prognostic Stage IB Breast Cancer AJCC v8","Prognostic Stage II Breast Cancer AJCC v8","Prognostic Stage IIA Breast Cancer AJCC v8","Prognostic Stage IIB Breast Cancer AJCC v8","Prognostic Stage III Breast Cancer AJCC v8","Prognostic Stage IIIA Breast Cancer AJCC v8","Prognostic Stage IIIB Breast Cancer AJCC v8","Prognostic Stage IIIC Breast Cancer AJCC v8","Stage I Cervical Cancer AJCC v8","Stage I Colorectal Cancer AJCC v8","Stage I Differentiated Thyroid Gland Carcinoma AJCC v8","Stage I Ovarian Cancer AJCC v8","Stage I Thyroid Gland Medullary Carcinoma AJCC v8","Stage I Uterine Corpus Cancer AJCC v8","Stage IA Cervical Cancer AJCC v8","Stage IA Ovarian Cancer AJCC v8","Stage IA Uterine Corpus Cancer AJCC v8","Stage IA1 Cervical Cancer AJCC v8","Stage IA2 Cervical Cancer AJCC v8","Stage IB Cervical Cancer AJCC v8","Stage IB Ovarian Cancer AJCC v8","Stage IB Uterine Corpus Cancer AJCC v8","Stage IB1 Cervical Cancer AJCC v8","Stage IB2 Cervical Cancer AJCC v8","Stage IC Ovarian Cancer AJCC v8","Stage II Cervical Cancer AJCC v8","Stage II Colorectal Cancer AJCC v8","Stage II Differentiated Thyroid Gland Carcinoma AJCC v8","Stage II Ovarian Cancer AJCC v8","Stage II Thyroid Gland Medullary Carcinoma AJCC v8","Stage II Uterine Corpus Cancer AJCC v8","Stage IIA Cervical Cancer AJCC v8","Stage IIA Colorectal Cancer AJCC v8","Stage IIA Ovarian Cancer AJCC v8","Stage IIA1 Cervical Cancer AJCC v8","Stage IIA2 Cervical Cancer AJCC v8","Stage IIB Cervical Cancer AJCC v8","Stage IIB Colorectal Cancer AJCC v8","Stage IIB Ovarian Cancer AJCC v8","Stage IIC Colorectal Cancer AJCC v8","Stage III Cervical Cancer AJCC v8","Stage III Colorectal Cancer AJCC v8","Stage III Differentiated Thyroid Gland Carcinoma AJCC v8","Stage III Ovarian Cancer AJCC v8","Stage III Thyroid Gland Medullary Carcinoma AJCC v8","Stage III Uterine Corpus Cancer AJCC v8","Stage IIIA Cervical Cancer AJCC v8","Stage IIIA Colorectal Cancer AJCC v8","Stage IIIA Ovarian Cancer AJCC v8","Stage IIIA Uterine Corpus Cancer AJCC v8","Stage IIIA1 Ovarian Cancer AJCC v8","Stage IIIA2 Ovarian Cancer AJCC v8","Stage IIIB Cervical Cancer AJCC v8","Stage IIIB Colorectal Cancer AJCC v8","Stage IIIB Ovarian Cancer AJCC v8","Stage IIIB Uterine Corpus Cancer AJCC v8","Stage IIIC Colorectal Cancer AJCC v8","Stage IIIC Ovarian Cancer AJCC v8","Stage IIIC Uterine Corpus Cancer AJCC v8","Stage IIIC1 Uterine Corpus Cancer AJCC v8","Stage IIIC2 Uterine Corpus Cancer AJCC v8","RECRUITING","2026-05-26",{"date":169,"type":46},"2026-05-28",{"date":171,"type":46},"2021-11-24",{"date":50,"type":21},{"name":174,"class":53},"University of Southern California",2,{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":183,"enrollmentInfo":184,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":166,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":214},"100239986","project-every-child-for-younger-patients-with-cancer-100239986","NCT02402244","Project: Every Child for Younger Patients With Cancer","The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study","Inclusion Criteria:\n\n* Enrollment must occur within 6 months of initial disease presentation OR within 6 months of refractory disease, disease progression, disease recurrence, second or secondary malignancy, or post-mortem\n* Patients previously enrolled on ACCRN07 are eligible to enroll on Tracking Outcome, Registry and Future Contact components of APEC14B1 any time after they reach age of majority\n* Patients with a known or suspected neoplasm that occurs in the pediatric, adolescent or young adult populations are eligible for enrollment as follows:\n\n  * All cancer cases with an International Classification of Diseases for Oncology (ICD-O) histologic behavior code of one \"1\" (borderline), two \"2\" (carcinoma in situ) or three \"3\" (malignant)\n  * All neoplastic lesions of the central nervous system regardless of behavior, i.e., benign, borderline or malignant\n  * All neoplastic lesions of the kidney regardless of behavior, i.e., benign, borderline or malignant\n  * The following other benign\u002Fborderline conditions:\n\n    * Mesoblastic nephroma\n    * Teratomas (mature and immature types)\n    * Myeloproliferative diseases including transient myeloproliferative disease\n    * Langerhans cell histiocytosis\n    * Lymphoproliferative diseases\n    * Desmoid tumors\n    * Gonadal stromal cell tumors\n    * Neuroendocrine tumors including pheochromocytoma\n    * Melanocytic tumors, except clearly benign nevi\n    * Ganglioneuromas\n* Subjects must be =\\\u003C 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating National Clinical Trials Network \\[NCTN\\]) therapeutic study, for which there is a higher upper age limit\n* All patients or their parents or legally authorized representatives must sign a written informed consent and agree to participate in at least one component of the study; parents will be asked to sign a separate consent for their own biospecimen submission\n\n  * If patients or their parents or legally authorized representatives have not signed the Part A subject consent form at the time of a diagnostic bone marrow procedure, it is recommended that they initially provide consent for drawing extra bone marrow using the Consent for Collection of Additional Bone Marrow; consent using the Part A subject consent form must be provided prior to any other procedures for eligibility screening or banking under APEC14B1","25 Years",{"count":185,"type":21},75000,"This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.",[188,189,37,190,191,192,193,194,195,196,197,198,33,199,200,201,202,203],"Adrenal Gland Pheochromocytoma","Carcinoma In Situ","Childhood Immature Teratoma","Childhood Kidney Neoplasm","Childhood Langerhans Cell Histiocytosis","Childhood Mature Teratoma","Congenital Mesoblastic Nephroma","Desmoid Fibromatosis","Ganglioneuroma","Lymphoproliferative Disorder","Malignant Neoplasm","Melanocytic Neoplasm","Myeloproliferative Neoplasm","Neoplasm of Uncertain Malignant Potential","Neuroendocrine Neoplasm","Stromal Neoplasm","2026-05-01",{"date":206,"type":46},"2026-05-05",{"date":208,"type":46},"2015-11-03",{"date":210,"type":21},"2030-12-31",{"name":212,"class":213},"Children's Oncology Group","NETWORK",278,{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":223,"conditions":224,"keywords":4,"overallStatus":166,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":54},"100415645","cerebrospinal-fluid-biomarkers-for-brain-tumors-100415645","NCT04692324","Cerebrospinal Fluid Biomarkers for Brain Tumors","Inclusion Criteria:\n\n* Any evidence of neoplasm involving the central nervous system (CNS) or its adjacent structures in contact with CSF. Such lesions may include but are not limited to intra-axial or extra-axial lesions, which could be benign, malignant or as yet undefined, involving the brain, spine, meninges, nerves, or vasculature or supporting structures\n* Subjects must be 18 years of age or older\n\nExclusion Criteria:\n\n* Patients who are under 18 years of age or are a member of a vulnerable population will be excluded from this study\n* Pregnant women or women who may be pregnant are specifically excluded from study participation\n* Exception will be granted for patients with diminished capacity to consent if a legally authorized representative is available\n* Patients without clinical or radiographic evidence of a potentially neoplastic CNS lesion will be excluded\n* Patients with an inability or unwillingness of individual or legal guardian\u002Frepresentative to give written informed consent will be excluded\n* Any patient for whom a clinical contraindication exists to the intended route of CSF access will be excluded. For example, a patient with a large posterior fossa mass lesion at risk of herniation, or a patient with coagulopathy, or other contraindication to lumbar puncture would not be eligible to participate via use of lumbar puncture for CSF access",{"count":222,"type":21},400,"This study examines cerebrospinal biomarkers in patients with brain tumors. A biomarker is a measurable indicator of the severity or presence of your disease state. Collecting and storing samples of cerebrospinal fluid from patients with brain tumors to study in the laboratory may help doctors develop new strategies to better diagnose, monitor, and treat brain tumors.",[37],"2026-04-17",{"date":227,"type":46},"2026-04-22",{"date":229,"type":46},"2021-01-14",{"date":231,"type":21},"2028-12-31",{"name":233,"class":53},"Mayo Clinic",{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":242,"conditions":243,"keywords":4,"overallStatus":166,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":54},"100438340","patient-perceptions-around-quality-of-care-through-telemedicine-in-neuro-oncology-100438340","NCT04988009","Patient Perceptions Around Quality of Care Through Telemedicine in Neuro-Oncology","Inclusion Criteria:\n\n* Patients with a CNS tumors: this includes patients with primary brain tumors, brain metastases, and leptomeningeal disease\n* Established patients with a follow up encounter with Neuro-Oncology at the Brain and Spine Center at the University of Texas MD Anderson Cancer Center; this encounter can be\n\n  * An in-person visit\n  * A telemedicine appointment\n\nExclusion Criteria:\n\n* Encounter occurred with the assistance of official language translation support\n* Patients with telephone encounters (without interactive video)\n* New patient or consult visits\n* Neither patient nor caregiver present during the visit are available or able to answer survey questions",{"count":241,"type":21},200,"This study evaluates patient perceptions around quality of care through telemedicine in neuro-oncology. Studying questionnaires related to perceptions quality of care through telemedicine in patients with brain cancer may help doctors to improve the delivery of care through this modality.",[37,244,245,246],"Leptomeningeal Neoplasm","Metastatic Malignant Neoplasm in the Brain","Primary Brain Neoplasm","2026-03-03",{"date":249,"type":46},"2026-03-05",{"date":251,"type":46},"2020-08-20",{"date":253,"type":21},"2026-12-31",{"name":255,"class":53},"M.D. Anderson Cancer Center",{"id":257,"slug":258,"hasResults":11,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":4,"eligibilityCriteria":262,"healthyVolunteers":11,"sex":17,"minAge":263,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":22,"phases":266,"briefSummary":268,"conditions":269,"keywords":4,"overallStatus":166,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":54},"100306502","phase-2-gadolinium-and-ferumoxytol-mri-in-diagnosing-patients-with-abnormalities-in-the-central-nervous-system-100306502","NCT03270059","Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System","The Feasibility of Steady State CBV Mapping Using Ferumoxytol Immediately After Gadolinium Enhanced MRI of the CNS","Inclusion Criteria:\n\n* Subjects must have one of the following:\n\n  * Neurological findings (i.e. headache, loss of consciousness, paresis, cranial neuropathy, seizures, etc.)\n  * Radiological abnormalities in the brain (neoplastic or non-neoplastic in nature)\n  * Neoplastic process elsewhere in the body that may affect the brain (i.e. possible metastasis, vascular compromise, treatment related changes, etc.)\n* Subjects must be able to undergo MRI imaging without anesthesia\n* Subjects must be at least 10 years of age\n* All subjects, or their legal guardians, must sign a written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization in accordance with institutional guidelines\n* Sexually active women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; surgical intervention i.e. tubal ligation or vasectomy; post-menopausal \\\u003C 6 months; or abstinence) for at least two months after each cycle of the study; should a female become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately\n\nExclusion Criteria:\n\n* Subjects with clinically significant signs of uncal herniation, such as acute pupillary enlargement, rapidly developing motor changes (over hours), or rapidly decreasing level of consciousness, are not eligible\n* Subjects with known allergic or hypersensitivity reactions to parenteral iron, parenteral dextran, parenteral iron-dextran, or parenteral iron-polysaccharide preparations (Ferumoxytol Investigator's Drug Brochure, 2009); subjects with significant drug or other allergies or autoimmune diseases may be enrolled at the investigator's discretion\n* Subjects who are pregnant or lactating or who suspect they might be pregnant\n* Subjects who have a contraindication for MRI: metal in their bodies (a cardiac pacemaker or other incompatible device), are severely agitated, or have an allergy to gadolinium containing contrast material\n* Subjects with known iron overload (genetic hemochromatosis); in subjects with a family history of hemochromatosis, hemochromatosis must be ruled out prior to study entry with normal values of the following blood tests: transferrin saturation (TS) test and serum ferritin (SF) test; all associated costs will be paid by the study\n* Subject who have received ferumoxytol within 3 weeks of study entry\n* Subjects with three or more drug allergies from separate drug classes","10 Years",{"count":265,"type":21},150,[267],"PHASE2","This phase II trial studies how well gadolinium and ferumoxytol magnetic resonance imaging (MRI) work in diagnosing patients with abnormalities in the central nervous system. Diagnostic procedures, such as gadolinium and ferumoxytol MRI, may help find and diagnose abnormalities in the central nervous system.",[37,270,245],"Cranial Nerve Disorder","2026-02-25",{"date":273,"type":46},"2026-02-27",{"date":275,"type":46},"2017-10-06",{"date":277,"type":21},"2028-12-15",{"name":279,"class":53},"OHSU Knight Cancer Institute"]